92P Targeting EMT-driven metastatic breast cancer with mitotic inhibitors

Metastatic breast cancer is the leading cause of cancer death in women and remains an incurable disease. The epithelial-to-mesenchymal transition (EMT) is widely recognized as a key driver of metastasis, with intermediate or hybrid EMT states shown to exhibit greater plasticity and metastasis-initiating potential than cells that undergo a complete EMT. However, the inherent heterogeneity and plasticity of EMT states pose significant challenges for therapeutic targeting. In this study, we characterized EMT heterogeneity in the